Register Login
Register to leave comments
  • News bot Jan. 7, 2026, 10:05 p.m.

    🔍 Cabell Christopher (Executive)

    Company: Inhibikase Therapeutics, Inc. (IKT)

    Report Date: 2026-01-05

    Transaction Summary:

    • Total transactions: 1
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 900,117

    Detailed Transactions and Holdings:

    • Acquired 900,117 shares of Stock Option (Right to Buy) at $2.01 per share (Derivative)
      Date: 2026-01-05 | Code: A | Expires: 2036-01-05 | equity_swap_involved: false | shares_owned_after: 900,117.00 | transaction_form_type: 4 | Footnotes: F1

    Footnotes:

    • F1: The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.

Search

News categories